Novartis Pharmaceuticals Corporation

États‑Unis d’Amérique


Commandez votre montre hebdomadaire Novartis Pharmaceuticals Corporation
Quantité totale PI 53
Rang # Quantité totale PI 26 527
Note d'activité PI 2,2/5.0    20
Rang # Activité PI 40 675
Parent Novartis AG
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

46 5
0 0
2 0
0
 
Dernier brevet 2025 - Compounds containing s-n-valeryl...
Premier brevet 1981 - Soft gelatin capsule with a liqu...
Dernière marque 1991 - LOTENSIN HCT
Première marque 1950 - CAFERGOT

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r...
Invention Ribociclib tablet. The present disclosure is directed to oral tablet of ribociclib including its ...
2022 Invention Method of adjuvant cancer treatment. The present invention provides a method of providing adjuva...
Invention Process for concentration of antibodies and therapeutic products thereof. This present disclosure...
Invention Compositions and methods for treatment. The present invention provides compounds and methods for...
Invention Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-...
Invention Amorphous solid form of compounds containing s—n-valeryl-n- {[2′-( 1 h-tetrazole-5-yl)-biphenyl-4...
Invention Amorphous solid form of compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl...
2021 Invention Pharmaceutical use. The present invention relates to novel methods and pharmaceutical compositio...
Invention Lfa-1 inhibitor formulations. The present invention provides formulations, methods and kits for ...
Invention Crystalline pharmaceutical and methods of preparation and use thereof. Novel crystalline polymor...
2020 Invention Modulators of cellular adhesion. The present invention provides compounds having formula (I): ...
2019 Invention Method of adjuvant cancer treatment. The present invention provides a method of providing adjuvan...
Invention Amorphous solid form of compounds containing s—n-valeryl-n-{[2′-(1h-tetrazole-5-yl)-biphenyl-4-yl...
Invention Eltrombopag dosing regimen. The present invention relates to a method of treating immune thromboc...
2018 Invention Dosage regimen of an s1p receptor modulator. The present invention relates to a dosage regimen of...
Invention Inhibitors for treating diseases characterized by atrial enlargement or remodeling. The present i...
2016 Invention Treatment of solid tumors with rapamycin derivatives. Rapamycin derivatives have interesting eff...
Invention Sacubitril-valsartan dosage regimen for treating heart failure. The present invention relates to ...
2015 Invention Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-car...
Invention High concentration antibody and protein formulations. The present application relates to highly c...
1991 P/S antihypertensive
1989 P/S ANTIHYPERTENSIVE
1979 P/S Antihypertensive
1976 P/S ANTI-HYPERTENSIVE PREPARATION
1950 P/S PREPARATION RECOMMENDED FOR THE TREATMENT OF HEADACHES